# Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

> **NCT05004129** · PHASE2,PHASE3 · RECRUITING · sponsor: **AMO Pharma Limited** · enrollment: 76 (estimated)

## Conditions studied

- Congenital Myotonic Dystrophy

## Interventions

- **DRUG:** Tideglusib

## Key facts

- **NCT ID:** NCT05004129
- **Lead sponsor:** AMO Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-23
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05004129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05004129, "Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05004129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*